MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Начало・Списък с акции・Biogen Inc

Biogen Inc

Затворен

СекторЗдравеопазване

146.67 2.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

142.5

Максимум

147.35

Ключови измерители
By Trading Economics
Приходи	394M 635M
Продажби	215M 2.6B
P/E Средно за сектора	13.846 36.442
Марж на печалбата	23.995
Служители	7,605
EBITDA	457M 1B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+22.99% upside

Дивиденти
By Dow Jones
Следващи печалби	30.10.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.3B 21B
Предишно отваряне	144.06
Предишно затваряне	146.67

Настроения в новините

By Acuity

10%

90%

11 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

118.15 / 121.17 Подкрепа & съпротива

Biogen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20.10.2025 г., 22:14 ч. UTC

Пазарно говорене

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20.10.2025 г., 22:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20.10.2025 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20.10.2025 г., 20:56 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20.10.2025 г., 20:16 ч. UTC

Пазарно говорене

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20.10.2025 г., 20:05 ч. UTC

Печалби

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20.10.2025 г., 19:39 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20.10.2025 г., 19:34 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20.10.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20.10.2025 г., 19:00 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 18:29 ч. UTC

Пазарно говорене

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20.10.2025 г., 18:11 ч. UTC

Пазарно говорене

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20.10.2025 г., 18:04 ч. UTC

Пазарно говорене

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20.10.2025 г., 17:03 ч. UTC

Пазарно говорене

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20.10.2025 г., 16:43 ч. UTC

Пазарно говорене

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20.10.2025 г., 16:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Biogen Inc Прогноза

Ценова цел

By TipRanks

22.99% нагоре

12-месечна прогноза

Среден 175.88 USD 22.99%

Висок 224 USD

Нисък 118 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Biogen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

23 ratings

Купи

Задържане

Продай

Според 23 анализатори, дали борсови рейтинги на Biogen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

118.15 / 121.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

11 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.